Samsrita Labs
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Samsrita Labs' board approved a capital reduction that will cancel one out of every two equity shares on a pro-rata basis, halving the paid-up capital from ₹22.75 crore to ₹11.37 crore. The scheme extinguishes 1,13,74,855 shares of face value ₹10 each and simultaneously wipes out ₹11.37 crore of accumulated losses and the entire share premium balance, a move the company said will present a true and fair view of its financial position. The board also appointed Ravi Kanth Naga Pattabhi Chopperla, a funding specialist who holds a 7.1% stake, as an additional non-executive professional director. The company amended its main objects clause to formally include pet animal healthcare and wellness, aligning the memorandum with the previously announced strategic pivot. The capital reduction remains subject to shareholder and Hyderabad NCLT approval; pro-rata cancellation means shareholding percentages stay unchanged and no consideration is paid to investors.
Powered by Tijori
Samsrita Labs' board approved a capital reduction that will cancel one out of every two equity shares on a pro-rata basis, halving the paid-up capital from ₹22.75 crore to ₹11.37 crore. The scheme extinguishes 1,13,74,855 shares of face value ₹10 each and simultaneously wipes out ₹11.37 crore of accumulated losses and the entire share premium balance, a move the company said will present a true and fair view of its financial position. The board also appointed Ravi Kanth Naga Pattabhi Chopperla, a funding specialist who holds a 7.1% stake, as an additional non-executive professional director. The company amended its main objects clause to formally include pet animal healthcare and wellness, aligning the memorandum with the previously announced strategic pivot. The capital reduction remains subject to shareholder and Hyderabad NCLT approval; pro-rata cancellation means shareholding percentages stay unchanged and no consideration is paid to investors.
Powered by Tijori
March 11 (Reuters) - Samsrita Labs Ltd SAMM.BO:
SAMSRITA LABS - INITIATED STRATEGIC EXPANSION INTO PET ANIMAL HEALTHCARE AND WELLNESS SEGMENT
Source text: ID:nBSEHqX7Z
Further company coverage: SAMM.BO
(([email protected];))
March 11 (Reuters) - Samsrita Labs Ltd SAMM.BO:
SAMSRITA LABS - INITIATED STRATEGIC EXPANSION INTO PET ANIMAL HEALTHCARE AND WELLNESS SEGMENT
Source text: ID:nBSEHqX7Z
Further company coverage: SAMM.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Samsrita Labs do?
Samsrita Labs is integrated global Bio-pharmaceutical Company. The company has been established as an advanced center for research and excellence in the areas of Stem Cell R&D and Therapy, New Drug discovery, Molecular Diagnostics, Stem cell based multi-Specialty Hospital and CRO.
Who are the competitors of Samsrita Labs?
Samsrita Labs major competitors are Jaihind Industries, Khyati Global Vent, AKG Exim, Yarn Syndicate, Gujarat Cotex, Amit Securities, Contil India. Market Cap of Samsrita Labs is ₹31 Crs. While the median market cap of its peers are ₹33 Crs.
Is Samsrita Labs financially stable compared to its competitors?
Samsrita Labs seems to be less financially stable compared to its competitors. Altman Z score of Samsrita Labs is 4.15 and is ranked 5 out of its 8 competitors.
Does Samsrita Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Samsrita Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Samsrita Labs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances
How strong is Samsrita Labs balance sheet?
Balance sheet of Samsrita Labs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Samsrita Labs improving?
No, profit is decreasing. The profit of Samsrita Labs is -₹8.43 Crs for TTM, -₹0.28 Crs for Mar 2025 and -₹0.26 Crs for Mar 2024.
Is the debt of Samsrita Labs increasing or decreasing?
The net debt of Samsrita Labs is decreasing. Latest net debt of Samsrita Labs is ₹0.03 Crs as of Mar-26. This is less than Mar-25 when it was ₹2.42 Crs.
Is Samsrita Labs stock expensive?
There is insufficient historical data to gauge this. Latest PE of Samsrita Labs is 0
Has the share price of Samsrita Labs grown faster than its competition?
Samsrita Labs has given lower returns compared to its competitors. Samsrita Labs has grown at ~-27.92% over the last 1yrs while peers have grown at a median rate of -21.54%
Is the promoter bullish about Samsrita Labs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Samsrita Labs is 25.44% and last quarter promoter holding is 25.44%.
Are mutual funds buying/selling Samsrita Labs?
There is Insufficient data to gauge this.